Navigation Links
MicroPhage Selects Lynn Taussig, MD for Board of Directors

LONGMONT, Colo., Dec. 2 /PRNewswire/ -- MicroPhage, Inc.,, announced today that Lynn M. Taussig, MD has joined the company's Board of Directors. Taussig was president and CEO of National Jewish Medical and Research Center in Denver, the nation's leading institution for studying respiratory diseases, from 1993 to 2006. His medical specialty is pediatric pulmonology.

"I have followed MicroPhage extensively and am impressed with its progress in developing new, rapid bacterial identification and antibiotic susceptibility tests, and am enthused about the clinical impact their products will have in providing accurate and cost-effective diagnosis of serious infections," said Taussig.

MicroPhage CEO Steve Lundy knows Taussig's expertise in diagnosis and management of respiratory diseases and his healthcare management experience will be valuable to the board in guiding the company's future. "We are pleased to have a physician and hospital executive of Dr. Taussig's stature join our board. His involvement and support shows confidence in MicroPhage, and his clinical expertise and vision will be deeply valued," said Lundy.

Taussig has served on numerous academic, government and business boards and commissions and has authored more than 170 publications related to respiratory illnesses in children. He has earned several academic, civic and professional honors, including the Distinguished Achievement Award from the American Thoracic Society. He currently serves as special advisor to the Provost for Life Sciences at the University of Denver and is on the Board of Directors of the Colorado Biosciences Association.

MicroPhage is in late stage development for its bacterial detection and susceptibility diagnostic system. The first products are targeted for rapid detection of MRSA (methicillin-resistant Staphylococcus aureus) and MSSA (methicillin-sensitive Staphylococcus aureus) for screening and diagnostic applications.

About MicroPhage

Based in Longmont, Colo. and privately held, MicroPhage, Inc. is working to be a global leader in developing rapid diagnostics products for bacterial identification and antibiotic susceptibility/resistance testing. Using its bacteriophage-based amplification platform for immunoassay diagnostics, the company has developed a patented process that is a product platform or engine for rapid, easy-to-use, inexpensive bacterial identification and antibiotic susceptibility testing. Its first products, expected in late 2009, will set a new standard for clinicians in MRSA identification and antibiotic susceptibility testing, and are designed to fit the demands for improving laboratory workflow. For further information, go to

SOURCE MicroPhage
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. New Research Shows MicroPhage Test Accurately and Rapidly Detects Serious Bacterial Infections
2. Mindray Selects Actel Low-Power Flash FPGAs for Demanding Medical Equipment Applications
3. Purdue Pharma Selects Systech to Provide Sustainable Infrastructure for Serialization
4. Loma Linda University Medical Center Selects Beryl to Manage Call Center Interactions for Womens Services Programs and Departments
5. West Penn Allegheny Health System Selects Electronic Health Record From Allscripts
6. ABMS Selects Kevin B. Weiss, MD, MPH, as New President and CEO
7. NIH selects Weill Cornell Medical College to lead new NYC translational research collaboration
8. Moffitt Selects Microsofts Azyxxi to Help Drive Personalized Cancer Treatment
9. Sandia National Laboratories Selects Allscripts Electronic Health Record and Practice Management for Employee Health Center
10. Delhaize Group Selects Trintechs AssureNET GL to Improve Compliance Process Efficiency
11. Financial Times Selects CAMFED International for 2007 Reader Seasonal Appeal
Post Your Comments:
(Date:11/27/2015)... ... 28, 2015 , ... There is only one major question facing all law ... , This question has not been an easy question to answer. Especially when the ... the younger workforce don’t share the same discipline around working long hours. , ...
(Date:11/27/2015)... ... November 27, 2015 , ... The rapid speed at which ... age, more care is needed, especially with Alzheimer’s, dementia and other cognitive conditions ... overworked. The forgotten part of this equation: 80 percent of medical care occurs ...
(Date:11/27/2015)... ... November 27, 2015 , ... Lizzie’s Lice Pickers just announced ... offering customers 10% off of their purchase of lice treatment product. In addition, customers ... According to a company spokesperson. “Finding lice is a sure way to ruin the ...
(Date:11/27/2015)... ... November 27, 2015 , ... Consistent ... sharing, the 2016 Building Better Radiology Marketing Programs meeting will showcase ... Sunday, March 6, 2016, at Caesars Palace in Las Vegas with a pre-conference ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... online platform for mental health and wellness consultation, has collaborated with a leading ... bridge the knowledge gap experienced by parents and bring advice from parenting experts ...
Breaking Medicine News(10 mins):
(Date:11/27/2015)... ) ... "2016 Global Tumor Marker Testing Market: Supplier ... Segment Forecasts, Innovative Technologies, Instrumentation Review, Competitive ... offering. --> ) has ... Global Tumor Marker Testing Market: Supplier Shares ...
(Date:11/26/2015)... 2015 Un nuevo enfoque combina ... el cáncer avanzado.   --> Un ... de Bremachlorin para el cáncer avanzado.   ... con la terapia fotodinámica de Bremachlorin para el cáncer ... --> Clinical Cancer Research . --> ...
(Date:11/26/2015)... , November 26, 2015 ... A new combination approach blends immunotherapy with Bremachlorin-photodynamic therapy ... new combination approach blends immunotherapy with Bremachlorin-photodynamic therapy for ... new combination approach blends immunotherapy with Bremachlorin-photodynamic therapy for ... has found that immunotherapy can be efficiently ...
Breaking Medicine Technology: